Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.
Despite making up the second largest ethnic group in the US, Latine and Hispanic individuals face alarming disparities in skin cancer outcomes, according to a review published in Cutis in collaboration with the Skin of Color Society.1
The review showed that while their lifetime risk of developing skin cancer is lower than that of non-Hispanic White individuals, Latine patients are more likely to receive a diagnosis at a more advanced stage and experience higher rates of morbidity and mortality. According to the authors, factors contributing to these ethnic disparities include delays in diagnosis, limited awareness about skin cancer risks, and inequities in access to care.
Many patients of color are unaware of the risk for melanoma on acral sites like palms of hands and soles of feet. | Image credit: anna.stasiia – stock.adobe.com
The unique clinical features of skin cancer in Latine patients often complicate early detection. For instance, melanoma in Latine individuals commonly manifests on the torso, lower extremities, and less visible areas like the soles of the feet or under nails, making it easier to overlook. Other research looking at melanoma knowledge among patients of color has shown that many are unaware of the risk for melanoma on acral sites like palms and soles, highlighting the need for more inclusive education.2
“Improving cultural misconceptions regarding skin conditions, especially skin cancer, is another important consideration in the Latine/Hispanic community,” the authors added.1,3 “Many Latine/Hispanic individuals wrongly believe they cannot develop skin cancer due to their darker skin tones and lack of family history.”
Insurance coverage disparities are another major contributor to poor skin cancer outcomes for Latine and Hispanic patients.1 Nearly 1 in 5 Latine individuals in the US lack health insurance, compared with only 8% of non-Hispanic White individuals, limiting their access to preventive screenings and timely treatments. Latine employees are also less likely to receive employer-sponsored health care coverage than their White counterparts (27% vs 53%). Even among those with insurance, high out-of-pocket costs and fear of financial strain discourage some from seeking care.
“Other factors that may impact skin cancer outcomes in this population include (but are not limited to) lack of or inadequate health insurance, medical mistrust, linguistic barriers and/or individual/cultural perspectives, along with limited research,” the authors added. “Recognizing and addressing these (albeit complex) barriers that contribute to the inequitable access to health care in this population remains a critical step toward improving skin cancer outcomes.”
Medical mistrust among Latine/Hispanic patients is often rooted in experiences of discrimination within health care settings and significantly impacts treatment adherence and health outcomes. A survey included in the review showed strong links between mistrust and perceived discrimination based on race, language, income, and insurance status. Even after adjusting for race and language, income-based discrimination persisted, and patients relying on public insurance like Medicare reported higher levels of mistrust compared with those holding private insurance.
“Together, these findings support the notion that individuals who have low socioeconomic status and lack insurance coverage—disproportionately historically marginalized populations—are more likely to perceive discrimination in health care settings, have greater medical mistrust, and experience poorer health outcomes.”
With the Latine community projected to grow to over 25% of the US population by 2060, addressing these disparities is a public health imperative.
References
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More